Tyrosine kinase inhibitorPhase 3 trialInvestigational
Apatinib
How it works
Apatinib is a small molecule that blocks the VEGFR-2 receptor on cancer cells, reducing blood flow to the tumor.
Cancer types
Efficacy
In clinical trials, apatinib improved overall survival in patients with pancreatic cancer, with a median overall survival of approximately 8.1 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Combination Therapy for Advanced Triple-Negative Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Combination Therapy Shows Promise for Advanced Mucosal Melanoma | Melanoma | phase-2 | The disease control rate reached 100% (SD = 13). | Source → |
| Combining Apatinib with EGFR-TKI May Help Lung Cancer Patients | Lung Cancer | phase-2 | The progression-free survival (PFS) of the Apatinib group was significantly longer than that of the chemotherapy group (10.5 months vs. 5.7 months). | Source → |
| Combining Apatinib with Chemotherapy May Help Some Metastatic Breast Cancer Patients | Breast Cancer | observational | The objective response rate was 44.4% vs. 19.2%, and the disease control rate was 77.8% vs. 48.1% in the apatinib plus chemotherapy group compared to the chemotherapy group. | Source → |
| Apatinib Shows Promise in Treating Advanced Melanoma | Melanoma | phase-2 | The median progression-free survival was 4.0 months, and the overall response rate was 13.3%. | Source → |
| Combining Apatinib and Temozolomide in Advanced Melanoma | Melanoma | phase-2 | The objective response rate was 17.2%, and the disease control rate was 82.8%. | Source → |
| Apatinib Shows Promise Against Small Cell Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Apatinib Efficacy in Lung Cancer Patients May Depend on Genetic Variation | Lung Cancer | observational | The overall response rate was 11.7%, and the disease control rate was 78.9%. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.